The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, a CAR-T cell therapy developed by biotechnology company March Biosciences.  The designation was granted based on data from March Bio’s ongoing multi-centre Phase II clinical trial. Preliminary findings from the safety run-in cohort suggest evidence of clinical activity […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!